Ask about this productRelated genes to: SLC22A11 Blocking Peptide
- Gene:
- SLC22A11 NIH gene
- Name:
- solute carrier family 22 member 11
- Previous symbol:
- -
- Synonyms:
- OAT4
- Chromosome:
- 11q13.1
- Locus Type:
- gene with protein product
- Date approved:
- 2002-01-31
- Date modifiied:
- 2016-10-05
Related products to: SLC22A11 Blocking Peptide
Related articles to: SLC22A11 Blocking Peptide
- Kidney drug transporters, primarily located in the basolateral and apical membranes of proximal tubule cells, play a key role in the secretion and reabsorption of drugs and endogenous compounds. Recent studies have demonstrated that kidney diseases can alter transporter expression; however, the expression of these transporters in human transplanted kidneys, with and without rejection, remains unclear. Therefore, the aim of this study was to investigate the mRNA expression (qRT-PCR) and immunolocalization (via immunohistochemistry) of key ABC (ATP-binding cassette) (n = 14) and SLC (solute carriers) (n = 33) transporters in glomeruli and proximal tubule cells from human normal kidney (CTRL, n = 8), non-rejected transplanted kidney (AR-0, n = 7) and transplanted kidney under rejection process (AR-I, n = 8) from patients receiving immunosuppressive drugs. Our study shows that mRNA expression level of SLC22A4, SLC22A6, SLC22A7, SLC22A8, SLC28A1, SLC47A1, SLC22A11, SLC15A2, SLC16A1, ABCC2, ABCC5 and ABCC6 are statistically significantly downregulated, while SLC22A2, SLCO4A1 and ABCB1 are statistically upregulated in proximal tubule cells from rejected transplanted kidneys compared to controls. Immunohistochemistry revealed that OAT1, OAT3, OCT2, MATE1, MRP2, MRP6 and P-gp were primarily expressed in proximal tubule cells, with significantly lower protein expression of OAT1, OAT3, P-gp in AR-I and AR-0 biopsies compared to CTRL sections. These preliminary data suggest that the expression profile of kidney transporters may be altered in transplanted kidneys from patients treated with immunosuppressive drugs. - Source: PubMed
Publication date: 2026/01/23
Łapczuk-Romańska JHybiak JPiotrowska KMarchelek-Myśliwiec MWilk ASłojewski MUrasińska EDroździk M - Genome-wide association studies have identified a series of genes, including solute carrier family 2 member 9 (SLC2A9), solute carrier family 22 member 11 (SLC22A11), solute carrier family 22 member 12 (SLC22A12) polymorphisms, that are associated with serum uric acid (SUA) levels. The prevalence of hyperuricemia in the Chinese Tibetan population is higher than in other regions of China; however, there is no evidence confirming a genetic association with SUA levels in this population. This study aimed to investigate the association between genetic polymorphisms and SUA levels, as well as hyperuricemia, in a Tibetan population in Tibet, China. A total of 194 Tibetan patients with hyperuricemia and 304 healthy Tibetan controls were enrolled, and polymorphisms in SLC2A9 (rs1014290), SLC22A12 (rs559946), and SLC22A11 (rs1783811) were identified using high-resolution melting. Logistic regression analysis, with adjustments for age and gender, was applied to evaluate the association between genetic polymorphisms and the risk of hyperuricemia, while calculating the corresponding odds ratios (OR) and 95% confidence interval (CI). Linear regression analysis was used to calculate beta values for associations with higher SUA levels. We found no significant association between SLC2A9 (rs1014290), SLC22A12 (rs559946), SLC22A11 (rs1783811), and hyperuricemia in the Tibetan population. Among hyperuricemia patients, SLC22A12 (rs559946) was negatively correlated with SUA levels after adjusting for gender and age. Under the dominant model, the rs559946 CC genotype was a protective factor against higher SUA levels in hyperuricemia patients (CC vs CT + TT: OR = 0.379, 95% CI: 0.162-0.886, P = .025). Under the additive model, rs559946 was also a protective factor (OR = 0.385, 95% CI: 0.175-0.850, P = .018). This study is the first to demonstrate that the CC genotype of SLC22A12 (rs559946) reduces the risk of higher SUA in Chinese Tibetan patients with hyperuricemia. - Source: PubMed
Li Ren-XuanGuo Yu-NingWang JiuLuo BuDanzen GuojieZhang Tong - Exposure to organophosphate pesticides (OPPs) has been linked to adverse birth outcomes, including low birthweight. Maternal biomarkers are commonly used as proxies for fetal exposure, but fetal exposure also depends on placental transport mechanisms. In 240 mother-newborn pairs, we explored how genetic variation in membrane transporters influences the association between maternal OPP concentrations and birthweight. Single nucleotide polymorphisms (SNPs) in the OAT4/SLC22A11 and OATP2B1/SLCO2B1 membrane transporters modified the relationship between OPP exposure and birthweight-for-gestational age, with significant inverse associations observed only among individuals with variant transporter genotypes. In this small study, we found that transporter genotype may influence the placental disposition of environmental chemicals and perinatal susceptibility to toxicity. - Source: PubMed
Publication date: 2025/10/14
Nguyen Duong QHyman SaraMedley EleanorBozack Anne KKahn Linda GKannan KurunthachalamGuitierrez AlejandraAleksunes Lauren MRivera-Núñez ZorimarCowell Whitney - Serum uric acid (SUA) and renal status are associated with the Cardiovascular-Kidney-Metabolic (CKM) syndrome. However, the causal association among them along with drug therapy need to be explored. - Source: PubMed
Publication date: 2025/08/04
Luo LingyunLuo XuelianHe Zhen - Autoantibodies against tumour-associated antigens (TAA) are promising biomarkers for cancer diagnosis. This systematic review aims to evaluate the diagnostic values of tumour-associated autoantibodies (TAAbs) in patients with pancreatic cancer. A search was conducted in the PubMed, Web of Science, and Embase databases to collect eligible studies. The primary outcomes included sensitivity, specificity, and accuracy of the test. We used QUADAS-2 to evaluate the risk of bias in the included studies. Meta-analysis was performed using MetaDisc 1.4 and STATA 14.0 software to calculate the combined sensitivity and specificity. A total of 49 articles were included in the final analysis that reported over 100 different TAAbs that were studied for the detection of pancreatic cancer. p53, Ezrin, CLDN17, KCNN3, SLAMF7, SLC22A11 and OR51F2 were the most frequently investigated autoantibodies in these studies. Ezrin exhibited better diagnostic performance with the pooled sensitivity, specificity and summary area under the receiver operating characteristic (SROC) curves being 56%, 88% and 0.90, respectively. Moreover, certain autoantibody combinations achieved substantially higher sensitivity at reasonably high levels of specificity. For example, the combination of Ezrin and ENOA1.2 autoantibodies with CA19.9 yielded sensitivity, specificity and area under the SROC curve of 100%, 92% and 0.96, respectively. TAAb is a promising diagnostic biomarker for early detection of PC, especially when combining TAAb with other markers. The promising candidate markers identified in this review deserve further validation in a broad screening population. - Source: PubMed
Liu YuqiGao YuyiWu YangxueWu WanyangYu JinyaoMa SiyaoShi JianxiangWang KeyanYe Hua